STN: 125771 Proper Name: antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl Tradename: ALTUVIIIO Manufacturer: Bioverativ Therapeutics Inc., a Sanofi Company Indication:
For use in adults and children with hemophilia A (congenital factor VIII deficiency) for:
Routine prophylaxis to reduce the frequency of bleeding episodes;
On-demand treatment and control of bleeding episodes; and
Perioperative management of bleeding.
Product Information
Supporting Documents
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
